Le Lézard
Classified in: Health
Subject: SVY

ProMIS Neurosciences Lead Product Candidate, PMN310, Shows Desired Target Binding Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies for Alzheimer's Disease



Narrated presentation of results available on ProMIS website

TSX: PMN

TORONTO and CAMBRIDGE, MA, Oct. 17, 2017 /CNW/ - ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that its lead product candidate for Alzheimer's disease, PMN310, showed the desired binding profile of selectively targeting amyloid beta oligomers in a preclinical study directly comparing PMN310 to other amyloid beta-directed antibodies for Alzheimer's disease (AD).

ProMIS Neurosciences Inc. (CNW Group/ProMIS Neurosciences Inc.)

A narrated presentation of these results is available on the ProMIS Neurosciences website at: http://bit.ly/2gp8S4t

Commenting on these results, ProMIS President and CEO, Elliot Goldstein, MD, stated: "We are pleased to confirm the selective binding of PMN310 to amyloid beta oligomers, a root cause of Alzheimer's disease. Results of prior clinical studies with other amyloid beta antibody therapeutics clearly showed that antibodies targeting amyloid beta monomer have consistently been ineffective, while those targeting amyloid beta fibrils, the main component of plaque, are associated with a dose limiting toxicity of brain swelling. Taken together, results of prior clinical trials indicate the best in class target product profile is selective binding of toxic amyloid beta oligomers."

The binding profile of PMN310 was compared to that of other candidate antibody therapeutics for AD in a preclinical study using the "dot blot" technique. Results of the study showed that PMN310 selectively binds amyloid beta oligomers (AbO), with virtually no binding to the other forms of amyloid beta. By comparison, solanezumab (Eli Lilly) showed binding mainly to Ab monomers; bapineuzumab (Johnson & Johnson/Pfizer, discontinued) showed binding to all forms of Ab (monomers, fibrils, oligomers); and aducanumab (Biogen) showed preferential binding to fibrils and oligomers.

Dot blotting is a method of applying (dotting) proteins, such as Ab monomers, fibrils and oligomers, directly onto a membrane or other support. Samples of the antibody to be evaluated are then applied and the binding pattern to the various forms of amyloid beta can be observed.

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a Toronto Stock Exchange listed biotech company (trading symbol: PMN.TO), headquartered in Toronto, Ontario with offices in Cambridge, Massachusetts. The Company's mission is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and ALS.

ProMIS Neurosciences' proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform?ProMIStm and Collective Coordinates ? to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information please consult the Company's website at:
www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

SOURCE ProMIS Neurosciences Inc.


These press releases may also interest you

at 03:30
SQN Clinical launches SQN Health Analytics, providing clinical professionals with a clear picture of the entire trial process and all collected data, whenever and wherever they need it.        (Photo:...

at 03:00
Mosa Meat, a spin off company from Maastricht University, today announced that it has raised ?7.5M to bring cultured meat to market by 2021. The Dutch start-up has led the cultured meat industry since presenting the world's first beef burger made...

at 03:00
Guna Nutraceuticals is live on Amazon with its top-selling botanical supplements including Gut Support for intestinal health, Optimal Iron for iron deficiency and Integral Probiotics for digestive tract flora rebalance....

at 03:00
TOWSON, Md., July 17, 2018 /PRNewswire-PRWeb/ -- Intersect Healthcare, a leading developer of Payer Compliance, Audit & Denial Management software for healthcare providers, announced the one year mark since VERACITYtm Suite has been deployed for...

at 03:00
ATLANTA, July 17, 2018 /PRNewswire-PRWeb/ -- Dr. Franklyn Elliott of Atlanta Plastic Surgery has been selected as a Top Doctor for the city of Atlanta in the field of plastic surgery for the fourth time. The list of Top Doctors was selected by Castle...

at 03:00
The new B·R·A·H·M·S PCT direct point of care assay is designed to make procalcitonin (PCT) measurement available to acute care settings where easy handling, quick and precise results are required to support timely clinical decisions, in conjunction...




News published on 17 october 2017 at 07:30 and distributed by: